Get the Stockscreener App
67.11
1.85%
-1.2191
Overview
News
Price History
Option Chain
Financials
Why ALC Down?
Discussions
Forecast
Dividend History
Alcon Inc stock is traded at $67.11, with a volume of 2.44M.
It is down -1.85% in the last 24 hours and up +0.38% over the past month.
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
See More
Previous Close:
$68.33
Open:
$68.8
24h Volume:
2.44M
Relative Volume:
1.21
Market Cap:
$32.72B
Revenue:
$10.63B
Net Income/Loss:
$819.00M
P/E Ratio:
40.48
EPS:
1.6577
Net Cash Flow:
$1.59B
1W Performance:
-0.05%
1M Performance:
+0.38%
6M Performance:
-17.22%
1Y Performance:
-22.74%
1-Day Range:
$65.99
$69.00
1-Week Range:
$65.99
$69.75
52-Week Range:
$61.84
$92.55
Alcon Inc Stock (ALC) Company Profile
Name
Alcon Inc
Sector
Industry
Phone
-
Address
-
Compare ALC vs ISRG, BDX, MDLN, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALC
Alcon Inc
|
67.09 | 33.32B | 10.63B | 819.00M | 1.59B | 1.6577 |
ISRG
Intuitive Surgical Inc
|
425.20 | 153.29B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
157.12 | 42.86B | 21.37B | 1.41B | 3.07B | 3.9437 |
MDLN
Medline Inc
|
42.91 | 36.15B | 29.14B | 1.07B | 1.05B | 1.1956 |
RMD
Resmed Inc
|
218.44 | 31.68B | 5.54B | 1.52B | 1.74B | 10.37 |
Alcon Inc Stock (ALC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-26-26 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-30-26 | Initiated | William Blair | Mkt Perform |
| Jan-20-26 | Upgrade | Deutsche Bank | Hold → Buy |
| Jan-09-26 | Downgrade | Stifel | Buy → Hold |
| Dec-11-25 | Downgrade | BofA Securities | Buy → Underperform |
| Aug-21-25 | Downgrade | JP Morgan | Overweight → Neutral |
| May-20-25 | Downgrade | Deutsche Bank | Buy → Hold |
| May-14-25 | Reiterated | BTIG Research | Buy |
| Mar-28-25 | Reiterated | Needham | Buy |
| Mar-25-25 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-24-25 | Reiterated | Needham | Buy |
| Jan-10-25 | Upgrade | Redburn Atlantic | Neutral → Buy |
| Dec-17-24 | Reiterated | Needham | Buy |
| Nov-12-24 | Reiterated | Needham | Buy |
| Oct-10-24 | Upgrade | Redburn Atlantic | Sell → Neutral |
| Sep-10-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jul-15-24 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| May-15-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-10-24 | Initiated | Goldman | Buy |
| Mar-14-24 | Initiated | RBC Capital Mkts | Sector Perform |
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Overweight |
| Jan-23-24 | Initiated | Bernstein | Outperform |
| Dec-18-23 | Downgrade | Redburn Atlantic | Neutral → Sell |
| Dec-12-23 | Initiated | Stifel | Buy |
| Dec-04-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Aug-17-23 | Upgrade | JP Morgan | Neutral → Overweight |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| May-10-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Mar-01-23 | Upgrade | Societe Generale | Sell → Hold |
| Dec-22-22 | Initiated | Mizuho | Buy |
| Nov-17-22 | Downgrade | Societe Generale | Hold → Sell |
| Aug-11-22 | Downgrade | Societe Generale | Buy → Hold |
| May-13-22 | Resumed | Credit Suisse | Outperform |
| May-12-22 | Upgrade | Stephens | Equal-Weight → Overweight |
| Apr-08-22 | Initiated | Needham | Buy |
| Mar-11-22 | Initiated | BofA Securities | Buy |
| Jan-18-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Jan-07-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Oct-01-21 | Initiated | Oppenheimer | Perform |
| Jul-14-21 | Initiated | Deutsche Bank | Buy |
| May-06-21 | Upgrade | Citigroup | Sell → Neutral |
| Mar-22-21 | Upgrade | BTIG Research | Neutral → Buy |
| Nov-12-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-06-20 | Downgrade | Citigroup | Neutral → Sell |
| Jul-06-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-08-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-26-20 | Upgrade | Argus | Hold → Buy |
| Mar-24-20 | Upgrade | Societe Generale | Sell → Hold |
| Mar-13-20 | Upgrade | UBS | Neutral → Buy |
| Mar-05-20 | Initiated | Citigroup | Neutral |
| Feb-26-20 | Upgrade | Berenberg | Hold → Buy |
| Jan-08-20 | Initiated | Argus | Hold |
| Oct-29-19 | Initiated | Stephens | Equal-Weight |
| Aug-21-19 | Reiterated | BofA/Merrill | Neutral |
| Jun-24-19 | Initiated | SVB Leerink | Mkt Perform |
| Jun-14-19 | Initiated | BTIG Research | Neutral |
| May-10-19 | Initiated | Robert W. Baird | Outperform |
| May-02-19 | Initiated | Credit Suisse | Outperform |
View All
Alcon Inc Stock (ALC) Latest News
RXST: Collaboration with Alcon and product innovation offset Q2 headwinds, supporting revised 2026 outlook - TradingView
Alcon, RxSight Begin Co-Developing Presbyopia-Correcting IOLs - Medical Product Outsourcing
Stifel reiterates Hold on RxSight stock, $8 target on Alcon deal By Investing.com - Investing.com Canada
Alcon focuses on eye care growth as a global leader - AD HOC NEWS
Alcon spends up to $200m to co-develop customisable cataract lenses with RxSight - Yahoo Finance
Alcon focuses on eye care growth as demand for vision treatments rises - AD HOC NEWS
Alcon focuses on eye care growth as investors watch long-term trends - AD HOC NEWS
Alcon, RxSight Partner to Develop Adjustable Presbyopia-Correcting IOLs - VisionMonday.com
Alcon Silver Announces Shareholder Approval of Arrangement - Yahoo! Finance Canada
Alcon (ALC) Partners with RxSight for Innovative Lens Developmen - GuruFocus
Alcon, RxSight partner on adjustable lens technology By Investing.com - Investing.com South Africa
RxSight, Inc. Announces Preliminary Second Quarter Financial Results and Product Pipeline Updates Following Strategic Collaboration Agreement - The Manila Times
Alcon and RxSight team up to develop light-adjustable cataract lenses - StreetInsider
Alcon and RxSight team up on adjustable lenses after cataract surgery - Stock Titan
Alcon focuses on eye care growth as investors watch long-term strategy - AD HOC NEWS
Price to sales forward of Alcon AG – SIX:ALC - TradingView
Alcon stock tracks its core eye care business. Investors await fresh cues. - AD HOC NEWS
Alcon Inc. (ALC) Stock Analysis: Eyeing A 26% Upside With Solid Buy Ratings - DirectorsTalk Interviews
Alcon focuses on ophthalmic growth as investor interest builds - AD HOC NEWS
Alcon stock holds its footing. Focus turns to the eye-care model. - AD HOC NEWS
Alcon Inc (ALC) Stock Up 4.2% and Still Undervalued -- GF Score: 71/100 - GuruFocus
SYSTANE Ultra from Alcon Inc.Dry eye relief built for digital days - AD HOC NEWS
Alcon Inc focuses on eye-care growth as global demand for vision treatment expands - AD HOC NEWS
DAILIES TOTAL1 contact lenses from Alcon Inc.daily disposables built for long screen days - AD HOC NEWS
Enterprise value to revenue forward of Alcon AG – VIE:ALC - TradingView
Total30 contact lenses from Alcon Inc.monthly comfort with water gradient tech - AD HOC NEWS
ALCAlcon Inc Latest SEC Filings - Finviz
Alcon consensus holds steady, shares in focus on SIX Swiss Exchange - AD HOC NEWS
Systane class action claims eye drops falsely advertised as preservative-free - Class Action Lawsuits
MiniMed adds Alcon CEO and Medtronic executive to board By Investing.com - Investing.com Canada
Press Release: MiniMed Appoints Alcon CEO David Endicott and Linnea Burman to Its Board of Directors - Moomoo
Alcon opens the week with a full earnings calendar, shares steady ahead of next update - AD HOC NEWS
Top Intraocular Lens Market Companies Driving Innovation - SNS Insider
Alcon Inc. (ALC) Stock Analysis: A Healthcare Giant With A 29.68% Upside Potential - DirectorsTalk Interviews
Alcon highlights surgical portfolio ahead of Q2, shares trade steadily on SIX - AD HOC NEWS
Alcon adjusts capital structure, shares supported by steady eye care demand - AD HOC NEWS
Lensar Stock Slumps After Hours On Ending Merger Deal With Alcon Over FTC Pushback - Stocktwits
Alcon Shares Fall After Guidance Trim on U.S. Trade Tariff Hit - WSJ
Alcon highlights cataract lens demand, shares on NYSE radar - Ad-hoc-news.de
PRECISION1 daily disposable lenses from Alcon Inc.a quiet push into comfort-first vision - Ad-hoc-news.de
ALC Forecast — Price Target — Prediction for 2027 - TradingView
The Systane ULTRA Lubricant Eye Drops from Alcon Inc.dry-eye relief with long-wear comfort - Ad-hoc-news.de
Alcon strategy in focus, ophthalmic stock attracts long-term investors - Ad-hoc-news.de
The AcrySof IQ Vivity from Alcon Inc.presbyopia lens for everyday sharpness - Ad-hoc-news.de
Alcon updates its strategic outlook, shares in focus for global eye-care investors - Ad-hoc-news.de
Alcon Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.1 Sh Actuals & Estimates (BMFBOVESPA:A2LC34) - TradingView
Alcon refines analyst consensus picture, shares in focus on SIX Swiss Exchange - Ad-hoc-news.de
Alcon, weekly sector review, shares in Swiss trading - Ad-hoc-news.de
Alcon shows steady progress, shares track consistent margins - Ad-hoc-news.de
Alcon consensus stays stable, analysts focus on surgical growth and stock performance - Ad-hoc-news.de
Alcon (ALC) Short Interest & Short Float | Updated Jun 2026 $ALC - MarketBeat
Alcon Inc Stock (ALC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.02%
0.66%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):